276 related articles for article (PubMed ID: 5778786)
1. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.
Bokisch VA; Müller-Eberhard HJ; Cochrane CG
J Exp Med; 1969 May; 129(5):1109-30. PubMed ID: 5778786
[TBL] [Abstract][Full Text] [Related]
2. Third component of complement (C3): structural properties in relation to functions.
Bokisch VA; Dierich MP; Mūller-Eberhard HJ
Proc Natl Acad Sci U S A; 1975 Jun; 72(6):1989-93. PubMed ID: 1056006
[TBL] [Abstract][Full Text] [Related]
3. Purification and partial characterization of human and porcine C3a anaphylatoxin.
Hugli TE; Vallota EH; Müller-Eberhard HJ
J Biol Chem; 1975 Feb; 250(4):1472-8. PubMed ID: 803505
[TBL] [Abstract][Full Text] [Related]
4. Anaphylatoxin release from the third component of human complement by hydroxylamine.
Budzko DB; Müller-Eberhard H
Science; 1969 Aug; 165(3892):506-7. PubMed ID: 5815704
[TBL] [Abstract][Full Text] [Related]
5. Kinetic studies on the fragmentation of the third component of complement (C3) by trypsin.
Minta JO; Man D; Movat HZ
J Immunol; 1977 Jun; 118(6):2192-8. PubMed ID: 864257
[TBL] [Abstract][Full Text] [Related]
6. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.
Bokisch VA; Müller-Eberhard HJ
J Clin Invest; 1970 Dec; 49(12):2427-36. PubMed ID: 4098172
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b).
Gitlin JD; Rosen FS; Lachmann PJ
J Exp Med; 1975 May; 141(5):1221-6. PubMed ID: 1168693
[TBL] [Abstract][Full Text] [Related]
8. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.
Cochrane CG; Müller-Eberhard HJ
J Exp Med; 1968 Feb; 127(2):371-86. PubMed ID: 4383923
[TBL] [Abstract][Full Text] [Related]
9. The antigenic and molecular alterations of C3 in the fluid phase during an immune reaction in normal human serum. Demonstration of a new conversion product, C3x.
Spitzer RE; Stitzel AE; Pauling VL; Davis NC; West CD
J Exp Med; 1971 Sep; 134(3 Pt 1):656-80. PubMed ID: 15776568
[TBL] [Abstract][Full Text] [Related]
10. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
11. Human anaphylatoxin (C3a) from the third component of complement. Primary structure.
Hugli TE
J Biol Chem; 1975 Nov; 250(21):8293-301. PubMed ID: 1238393
[TBL] [Abstract][Full Text] [Related]
12. Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator.
Vallota EH; Müller-Eberhard HJ
J Exp Med; 1973 May; 137(5):1109-23. PubMed ID: 4121926
[TBL] [Abstract][Full Text] [Related]
13. Interaction of soluble C3 fragments with guinea pig lymphocytes. Comparison of effects of C3a, C3b, C3c, and C3d on lymphokine production and lymphocyte proliferation.
Koopman WJ; Sandberg AL; Wahl SM; Mergenhagen SE
J Immunol; 1976 Jul; 117(1):331-6. PubMed ID: 932430
[TBL] [Abstract][Full Text] [Related]
14. Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3.
da Silva WD; Eisele JW; Lepow IH
J Exp Med; 1967 Dec; 126(6):1027-48. PubMed ID: 6069927
[TBL] [Abstract][Full Text] [Related]
15. Purification, characterization, and amino acid sequence of rat anaphylatoxin (C3a).
Jacobs JW; Rubin JS; Hugli TE; Bogardt RA; Mariz IK; Daniels JS; Daughaday WH; Bradshaw RA
Biochemistry; 1978 Nov; 17(23):5031-8. PubMed ID: 309768
[TBL] [Abstract][Full Text] [Related]
16. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.
Alper CA; Abramson N; Johnston RB; Jandl JH; Rosen FS
J Clin Invest; 1970 Nov; 49(11):1975-85. PubMed ID: 4097977
[TBL] [Abstract][Full Text] [Related]
17. Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.
Meuth JL; Morgan EL; DiSipio RG; Hugli TE
J Immunol; 1983 Jun; 130(6):2605-11. PubMed ID: 6602172
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody.
Burger R; Bader A; Kirschfink M; Rother U; Schrod L; Wörner I; Zilow G
Clin Exp Immunol; 1987 Jun; 68(3):703-11. PubMed ID: 3498585
[TBL] [Abstract][Full Text] [Related]
19. Cyanate as an inactivator of complement proteins.
Schultz DR; Arnold PI
J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
[TBL] [Abstract][Full Text] [Related]
20. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.
Vallota EH; Götze O; Spiegelberg HL; Forristal J; West CD; Müller-Eberhard HJ
J Exp Med; 1974 May; 139(5):1249-61. PubMed ID: 4207623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
